Skip to main content

Advertisement

Table 1 Insulin versus hypoglycaemic drugs

From: Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials

Studies Methodological quality: Low/moderate/good (Blinding Yes/No) Participants (Ins/C) TreatmentsTreatments Follow-up (weeks) Inclusion criteria Primary outcome
Alvarsson 2009 [32] Moderate (No) 51 (23/28) Insulin/glibenclamide 104 FBG: [6; 12 mmol/L]
35–75 years
HbA1c, metabolic control
Aschner 2012 [33] Good (No) 515 (250/265) Met/S + Insulin Glargine/Sitagliptin 24 [7 %; 11]
35–70 years
BMI = [25–45 kg/m2]
HbA1c
Bunck 2009 [34] Moderate (No) 69 (33/36) Met + Insulin glargine/exenatide 52 [6,5 %; 9,5]
35–75 years
BMI = [25–40 kg/m2]
Metabolic control
Davies 2009 [35] Good (No) 233 (117/118) OHD (Met/S/TZD) + Insulin glargine/exenatide 51 [7,5 %;10 %]
BMI > 27 kg/m2
HbA1c
Diamant 2010 [36] Moderate (No) 467 (234/233) OHD (Met/Met-S) + Insulin glargine/exenatide 26 [7 %; 11 %] - BMI : [25-40 kg/m2] HbA1C
Gallwitz 2011 [37] Moderate (No) 363 (181/182) Met + Insulin Aspart/exenatide 26 [6,5 %; 10] HbA1c
Gerstein 2006 [38] Moderate (No) 405 (206/199) OHD + Insulin glargine/conventional 24 [7,5 %; 11 %]
BMI: [21–41 kg/m2]
18–80 years
HbA1c
Gerstein 2012 [39] Good (No) 12527 (6273/6264) Lifestyle recommendations and OHD + Glargine/Conventional care/omega3/placebo 6 years Recent diabetes/Glucose Intolerance/ Composite of CV events
Hartemann 2011 [40] Moderate (No) 27 (13/14) OHD (Met/S) + Insulin NPH/Pioglitazone 24 [7,5 %; 9,5 %]
BMI > 26 kg/m2
18–80 years
HbA1c
Heine 2009 [41] Moderate (No) 551 (267/282) OHD (Met/S) + Insulin Glargine/Exenatide 26 [7 %; 10 %]
BMI: [25–45 kg/m2]
35–75 years
HbA1c
Hollander 2009 [42] Moderate (No) 217 (107/110) OHD (Met + Sitagliptin) + Insulin Detemir/+/− S 26 [7,5 %; 10 %]
BMI < 40 kg/m2
HbA1c
Nauck 2007 [43] Moderate (No) 501 (248/253) OHD (Met/S) + Insulin Aspart/Exenatide 52 [7 %; 11 %]
BMI : [25–40 kg/m2]
30–75 years
HbA1c
Nauck 2012 [44] Good (No) 1037 (364/351/322) Met + S + Taspoglutide 10/taspoglutide 20/Insulin Glargine 24 [7 %; 10 %]
BMI : [25–45 kg/m2]
18–75 ans
HbA1c
Reynolds 2007 [45] Moderate (No) 40 (20/20) OHD (Met/S) + Insulin Aspart/Rosiglitazone 26 [8 %; 12 %] HbA1c, metabolic control
Rosenstock 2006 [46] Good (No) 217 (105/112) OHD (Met/S) + Insulin Glargine/Rosiglitazone 24 [7,5 %; 11 %]
BMI > 25 kg/m2
>18 years
HbA1c
UKPDS 24 1998 [47] Good (No) 458 (178/231/49) Insulin/Chlorpropamide or Glyburide/Metformin 6 years Diet failure
UKPDS 33
25–60 years
HbA1c/FPG